APR 22, 2019 8:49 PM PDT

First Generic Naloxone Nasal Spray Approved To Treat Opioid Overdose

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved the first generic naloxone hydrochloride nasal spray. The spray is called Narcan and is a life-saving medication that can stop or reverse the effects of an opioid overdose.

According to the Centers for Disease Control and Prevention, about 400,000 people have died from an opioid overdose between 1999 to 2017. On average, 130 Americans die every day from opioid overdoses--a class of drugs that include prescription medications such as fentanyl, oxycodone, hydrocodone and morphine. Some opioids include illegal drugs such as heroin which contains fentanyl or derivatives of fentanyl.

“In the wake of the opioid crisis, a number of efforts are underway to make this emergency overdose reversal treatment more readily available and more accessible. In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone. The FDA has also taken the unprecedented step of helping to assist manufacturers to pursue approval of an over-the-counter naloxone product and is exploring other ways to increase the availability of naloxone products intended for use in the community, including whether naloxone should be co-prescribed with all or some opioid prescriptions to reduce the risk of overdose death,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs in the FDA’s Center for Drug Evaluation and Research.

“All together, these efforts have the potential to put a vital tool for combatting opioid overdose in the hands of those who need it most – friends and families of opioid users, as well as first responders and community-based organizations. We’re taking many steps to improve availability of naloxone products, and we’re committed to working with other federal, state and local officials as well as health care providers, patients and communities across the country to combat the staggering human and economic toll created by opioid abuse and addiction.”

Source: FDA

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 06, 2021
Cannabis Sciences
New CBD Analog Outperforms Regular CBD for Pain Relief
MAY 06, 2021
New CBD Analog Outperforms Regular CBD for Pain Relief
Researchers from Temple University Health System have found that a novel cannabidiol (CBD) analog can reverse pain sensi ...
MAY 12, 2021
Cardiology
Reversing the Heart Damage Seen in Marfan Syndrome
MAY 12, 2021
Reversing the Heart Damage Seen in Marfan Syndrome
Marfan syndrome is a genetic disorder that disrupts the connective tissues that anchor and link the body's organs, affec ...
MAY 19, 2021
Drug Discovery & Development
Combination Immunotherapy Shows Promise in Treating HIV
MAY 19, 2021
Combination Immunotherapy Shows Promise in Treating HIV
  Researchers have found that a new combination immunotherapy, alongside antiretroviral therapy (ART), is effective ...
JUN 29, 2021
Technology
Can Digital Simulations Replace Real People in Clinical Trials? Maybe
JUN 29, 2021
Can Digital Simulations Replace Real People in Clinical Trials? Maybe
Clinical trials are essential to the development of new drugs and medicines, and they offer new insights every day about ...
JUL 16, 2021
Cardiology
Therapeutic Exosome Spray May One Day Aid Heart Attack Recovery
JUL 16, 2021
Therapeutic Exosome Spray May One Day Aid Heart Attack Recovery
When the flow of blood to the heart is blocked, heart cells don't get enough oxygen and begin to die; this is a heart at ...
JUL 29, 2021
Drug Discovery & Development
What is Ivermectin and Can it Treat COVID?
JUL 29, 2021
What is Ivermectin and Can it Treat COVID?
Lab tests in 2020 found that the widely available drug ivermectin had a weak effect on the SARS-CoV-2 virus and that unf ...
Loading Comments...